Project Grant R01CA303658
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30322, USA
Similar Awards
- The National Cancer Institute awarded Children's Hospital Los Angeles $8.473 million on September 10, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test a patient navigation intervention designed to improve transition success among multiply disadvantaged young adult survivors of childhood cancer. The intervention addresses a documented gap in survivorship care: while childhood cancer survival rates exceed 85 percent, treatment-related late effects...
- The National Cancer Institute awarded Emory University $196,792 on August 6, 2026, under the Cancer Treatment Research program (CFDA 93.395) to expand and accelerate clinical trial research in pediatric central nervous system tumors through national clinical trials leadership and innovative trial development. Jason Fangusaro, MD, Professor of Pediatrics and Director of Developmental Therapeutics at Children's Healthcare of Atlanta and Emory University, leads the award. Over the five-year...
- The National Cancer Institute awarded Weill Medical College of Cornell University a $1,053,426 cooperative agreement on March 20, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to establish the AYA Cohort to Enhance Survivorship in NYC (ACES-NYC), a prospective cohort enrolling and following 2,000 adolescent and young adult cancer survivors treated at three New York City cancer centers—Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center, and Columbia...
- The National Cancer Institute awarded Emory University $682,730 on August 13, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a patient-centered value assessment informing value-based insurance design models for outpatient specialty palliative care in advanced cancer. The project, titled UNCOVER-PC: Uniting Novel Concepts of Value to Enhance Reform in Palliative Care, addresses low uptake of specialty palliative care among advanced cancer patients—only 10...
- The National Cancer Institute awarded New York University $310,185 on July 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and feasibility-test a mobile application delivering an evidence-based intervention that addresses financial stress and smoking cessation. The recipient will develop a smartphone app version of the FIERCE (Financial Freedom from Cigarettes) intervention, which integrates financial coaching into smoking cessation treatment. The work...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Ann & Robert H Lurie Children's Hospital of Chicago a $651,859 Project Grant on September 19, 2025, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and evaluate #AYAOSM (The AYA Oncology Self-Care Movement), an influencer-driven social media intervention designed to improve oral chemotherapy adherence in adolescents and young adults (AYAs) with acute lymphoblastic leukemia. Prior...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $252,023 on September 3, 2026, under the Cancer Research Manpower program (CFDA 93.398) to adapt an evidence-based goals-of-care communication intervention for adolescent and young adult cancer patients (ages 15–39). The project addresses poor end-of-life outcomes in this population, including high rates of futile aggressive care interventions in the final month of life and low hospice enrollment. Current...
- The National Cancer Institute awarded The Washington University $882,444 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to test clarified imaging reports designed to reduce anxiety, fear of cancer recurrence, and improve understanding of follow-up care needs among adult survivors of pediatric brain cancer. The research comprises three aims. Aim 1 will explore through interviews how adult survivors of pediatric brain cancer and their care teams prefer...
- The National Cancer Institute awarded The Leland Stanford Junior University $258,945 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to adapt and pilot test Roadmap to Parenthood, an evidence-based digital decision aid and planning tool for family building after cancer. Roadmap was originally developed for women who completed gonadotoxic cancer treatment and demonstrated improvements in knowledge, self-efficacy, decisional conflict, and patient-provider...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute For Cancer Research $731,503 on June 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial of brief behavioral activation for older adult cancer survivors. The research addresses depression among cancer survivors aged 65 and older, a population expected to comprise 73 percent of all cancer survivors by 2040, with up to 35 percent...